<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615262</url>
  </required_header>
  <id_info>
    <org_study_id>Dex01</org_study_id>
    <nct_id>NCT02615262</nct_id>
  </id_info>
  <brief_title>Intraoperative Dexamethasone in Pediatric Cardiac Surgery</brief_title>
  <official_title>Intraoperative Dexamethasone in Pediatric Cardiac Surgery: a Prospective Double-blind Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative administration of steroids has been demonstrated to reduce systemic
      inflammatory response in infants undergoing cardiac surgery with cardiopulmonary bypass.
      However, data on effects of steroids on clinical outcomes are lacking. Hence the hypothesis
      of the present study: intraoperative administration of dexamethasone reduces complication
      rates and improves clinical outcomes in infants undergoing repair of congenital heart defects
      under cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Composite of all-cause death, myocardial infarction, need for extracorporeal membrane oxygenation implantation, cardiac arrest, acute renal failure (stage &quot;injury&quot; or higher according to pRIFLE scale), prolonged mechanical ventilation (&gt; 24 hours), stroke, seizure, coma.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Congenital Heart Defects</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective repair of congenital heart defects under cardiopulmonary bypass

        Exclusion Criteria:

          -  absence of written informed consent signed by parent or guardian;

          -  hypoplastic left heart syndrome;

          -  participation in conflicting randomised studies;

          -  emergency surgery;

          -  inotropic support prior to surgery;

          -  mechanical ventilation prior to surgery;

          -  bacterial, viral or fungal infection in the preceding 30 days;

          -  gestational age less that 37 weeks;

          -  perinatal central nervous system damage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Lomivorotov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novosibirsk Research Institute of Circulation Pathology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dante Pazzanese Cardiology Institute</name>
      <address>
        <city>San Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Childrens Medical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Center of Cardiovascular Surgery, Penza city</name>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric cardiac surgery</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Steroids</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Congenital heart defects</keyword>
  <keyword>Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

